In March 2026, the Company entered into the At Market Issuance Sales Agreement with B. Riley Securities, Inc. ("B. Riley Securities"), Jones, and Ladenburg Thalmann & Co. Inc. ("Ladenburg Thalmann"),…
In March 2026, the Company entered into the At Market Issuance Sales Agreement with B. Riley Securities, Inc. ("B. Riley Securities"), Jones, and Ladenburg Thalmann & Co. Inc. ("Ladenburg Thalmann"),…
In January 2016, Former Elicio entered into a license agreement to license certain intellectual property rights from the Massachusetts Institute of Technology ("MIT"), which agreement has been amende…
The Company issued 3,500,573 shares of its common stock to GKCC in exchange for the principal balance of $ 20.0 million plus $ 0.3 million in accrued interest, in satisfaction in full of the Converti…
Elicio Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ELTX-DEBT
Debt stack $14.3M
90%
Market cache reports total debt of $14.3M.
ELTX-DEBT-9271
Warrants outstanding: 1261830
90%
xbrl warrant detail from xbrl 2025-12-31.
ELTX-DEBT-9272
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Elicio Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Elicio Therapeutics, Inc..
Elicio Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
ELTX-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 49 tracked holders.
Elicio Therapeutics, Inc. Extended Supply Chain Network
